HL23 is a histone deacetylase (HDAC) inhibitor that effectively targets hepatocellular carcinoma (HCC). It promotes acetylation at the TXNIP promoter and increases TXNIP expression, modulating potassium channel activity and inducing TXNIP-dependent potassium deficiency. Additionally, HL23 impedes HCC progression and spread, demonstrating greater potency when combined with Sorafenib than the Sorafenib and Vorinostat duo [1].
Molecular Weight:
712.83
CAS Number:
[1448355-15-4]
Formula:
C44H44N2O7
Target:
Others|||HDAC
T79407
* VAT and and shipping costs not included. Errors and price changes excepted
